Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026
Basics
Sector
Healthcare
Industry
Medical Distribution
Country
United States
Market cap
9.2B USD
Enterprise value
14.5B USD
Full-time employees
25,000
Overall health
Strength:its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback:growing more slowly than most peersgrowing more slowly than peers
Drawback:higher risk than most peers: less short-term liquidity (current ratio 1.32 vs a peer median of 2.59) and more debt relative to equity (0.81× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.32 vs peers 2.59) and more debt vs equity (0.81× vs peers 0.22×)
About average: profitability
Ranks #689 of 1,157 healthcare companies (bottom 41%)
Why it changed since the Oct 27, 2026 close: Score 68 → 69
Share price -2.1%+1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Henry Schein
Is Henry Schein getting weaker?
Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is unchanged at 47/100 since Oct 28, 2026.
How is Henry Schein valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 69/100 against 1,393 healthcare peers.Earnings yield 4.2% vs a peer median of 1.5% (stronger than 72% of peers).Earnings yield 4.2% vs peers 1.5% (stronger than 72% of peers).
Is Henry Schein growing?
At about the same pace as its peers. Growth scores 40/100 against 1,393 healthcare peers.3-year revenue growth 1.4% vs a peer median of 5.8% (weaker than 67% of peers).3-year revenue growth 1.4% vs peers 5.8% (weaker than 67% of peers).
How profitable is Henry Schein?
About as profitable as its peers. Profitability scores 59/100 against 1,393 healthcare peers.Return on assets 4.4% vs a peer median of 1.7% (stronger than 69% of peers).Return on assets 4.4% vs peers 1.7% (stronger than 69% of peers).
How risky is Henry Schein?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Current ratio 1.32× vs a peer median of 2.59× (weaker than 80% of peers).Current ratio 1.32× vs peers 2.59× (weaker than 80% of peers). A relative measure, not a bankruptcy probability.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Medical Distribution companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Detailed annual statements come from structured SEC filing data, which most US companies and some foreign filers provide. They aren’t available for this company yet.
HSIC price history
Price history is added with the daily price update and will appear after the next one.